Insiders · XLO

XLO insider transactions

Xilio Therapeutics Inc. (XLO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

XLO insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Xilio Therapeutics Inc., latest first. Follow anyone to get their next filing.

• Yariv HouvrasChief Medical Officer, since September 2026
• Robert W. RossDirector, since June 2022
• Sara BonsteinDirector
• Akintunde Olatokumbo BelloDirector, since June 2025
• James Samuel ShannonDirector, since June 2024+$92K
• Yuan XuDirector, since January 2022
• Daniel J. CurranDirector
• Aoife BrennanDirector, since June 2024
• Cheryl R BlanchardDirector, since April 2026
• Gilead Sciences, Inc.10% owner, since March 2024+$2.2M
• Katarina LuptakovaChief Medical Officer, since September 2023
• Christopher James FrankenfieldChief Financial Officer, since August 2023-$11.4K
• Kevin M. BrennanSVP, Finance and Accounting, since March 2023-$2,948
• Rene RussoPresident and CEO, Director+$24.7K
• Paul J ClancyDirector
• Christina RossiDirector
• Yekaterina Chudnovsky10% owner, since June 2024
• Atlas Venture Fund XI, L.P.10% owner+$3M-$4,240
• Martin H. Huber Jr.Officer
• Tomas J. HeymanDirector, since September 2022
• Edward C EnglishOfficer, since November 2022
• Michael Jay RossDirector
• Salvatore GiovineOfficer
• Bain Capital Life Sciences Investors, LLC10% owner, since October 2021+$410K
• SV7 Impact Medicine Fund LP10% owner+$10M
• James E Flynn10% owner+$12.4M
• FIL LtdInsider
• Fmr LLCInsider
• Takeda Pharmaceutical Co Ltd10% owner, since October 2021
• RiverVest Venture Fund IV, L.P.10% owner+$4M
• KGaA Merck10% owner
• Rock Springs Capital Management LP10% owner+$8M
• Bay City Capital LLC10% owner+$5M
• Alexandria Venture Investments, LLC10% owner
• John Charles Williams10% owner, since October 2021

Recent Form 3, 4, and 5 filings for XLO

• 37d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER Houvras Yariv

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 37d
  SEC Form 3 filed by new insider Houvras Yariv

  3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 150d
  SEC Form 4 filed by Director Shannon James Samuel

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 150d
  SEC Form 4 filed by Director Bonstein Sara

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 150d
  SEC Form 4 filed by Director Curran Daniel J.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 150d
  SEC Form 4 filed by Director Xu Yuan

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 150d
  SEC Form 4 filed by Director Ross Robert W.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 150d
  SEC Form 4 filed by Director Bello Akintunde Olatokumbo

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 150d
  SEC Form 4 filed by Director Brennan Aoife

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 206d
  SEC Form 4 filed by Blanchard Cheryl R

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 206d
  SEC Form 3 filed by new insider Blanchard Cheryl R

  3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 223d
  SEC Form 4 filed by Shannon James Samuel

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 264d
  SEC Form 4 filed by Large owner Gilead Sciences, Inc.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 307d
  CHIEF MEDICAL OFFICER Luptakova Katarina converted options into 16,625 shares, increasing direct ownership by 100% to 33,250 units (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 307d
  Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $4,522 worth of shares (7,030 units at $0.64), increasing direct ownership by 99% to 24,766 units (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 307d
  SVP, FINANCE AND ACCOUNTING Brennan Kevin M. converted options into 5,000 shares and sold $1,174 worth of shares (1,826 units at $0.64), increasing direct ownership by 99% to 6,371 units (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 307d
  PRESIDENT AND CEO Russo Rene converted options into 44,250 shares, increasing direct ownership by 16% to 325,422 units (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 342d
  SEC Form 4 filed by Xilio Therapeutics Inc.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 348d
  SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 348d
  SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 348d
  SEC Form 4 filed by CHIEF MEDICAL OFFICER Luptakova Katarina

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 348d
  SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 508d
  Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 508d
  PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 508d
  Amendment: SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

  4/A - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Ross Robert W.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Brennan Aoife

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Bonstein Sara

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Curran Daniel J.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Clancy Paul J

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Xu Yuan

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Shannon James Samuel

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Rossi Christina

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 4 filed by Director Bello Akintunde Olatokumbo

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 514d
  SEC Form 3 filed by new insider Bello Akintunde Olatokumbo

  3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 520d
  SEC Form 4 filed by Large owner Gilead Sciences, Inc.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 571d
  SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 571d
  SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 674d
  Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $6,841 worth of shares (6,954 units at $0.98) (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 674d
  SVP, FINANCE AND ACCOUNTING Brennan Kevin M. converted options into 5,000 shares and sold $1,774 worth of shares (1,803 units at $0.98) (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 674d
  PRESIDENT AND CEO Russo Rene converted options into 44,250 shares, increasing direct ownership by 22% to 244,883 units (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 674d
  CHIEF MEDICAL OFFICER Luptakova Katarina converted options into 16,625 shares (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 689d
  Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 767d
  SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 772d
  New insider Chudnovsky Yekaterina claimed ownership of 7,000,000 shares (SEC Form 3)

  3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 824d
  SEC Form 4 filed by Chief Operating Officer Frankenfield Christopher James

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 874d
  SEC Form 4 filed by Director Clancy Paul J

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 874d
  SEC Form 4 filed by Director Bonstein Sara

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 874d
  SEC Form 4 filed by Director Xu Yuan

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 874d
  SEC Form 4 filed by Director Rossi Christina

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 874d
  SEC Form 4 filed by Director Curran Daniel J.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 874d
  SEC Form 4 filed by Director Ross Robert W.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 875d
  SEC Form 4 filed by Director Shannon James Samuel

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 875d
  SEC Form 3 filed by new insider Shannon James Samuel

  3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 875d
  SEC Form 4 filed by Director Brennan Aoife

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 875d
  SEC Form 3 filed by new insider Brennan Aoife

  3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 920d
  SEC Form 4 filed by Frankenfield Christopher James

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 920d
  SEC Form 4 filed by Luptakova Katarina

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 920d
  SEC Form 4 filed by Brennan Kevin M.

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
• 920d
  SEC Form 4 filed by Russo Rene

  4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)